Bright-Eyed And Bushy Tailed: Purdue Launches Intermezzo
This article was originally published in The Pink Sheet Daily
Purdue Pharma launched Transcept Pharmaceutical’s Intermezzo, a low-dose sublingual tablet version of the generic sleep aid zolpidem, for middle-of-the-night awakenings April 5. Priced at a wholesale acquisition cost of $6.45 per tablet, the drug could face an uphill commercial road competing against generics.
You may also be interested in...
The companies will bulk up their sales force and begin a direct-to-consumer campaign in an effort to boost sales for their sleep aid, which has gotten off to a slow start since its launch in April.
Financings Of The Fortnight: Biotech IPO Trends Continue With Supernus’ Offering – Haircuts, Insider Buys
Plus news on recent financing activity by Argos, Telstar, Castlight Health and Transcept.
Indication for insomnia characterized by middle-of-the-night awakening followed by difficulty returning to sleep is a first.